Buchumschlag

Double-blind, placebo-controlled first in human study to investigate an oral vaccine aimed to elicit an immune reaction against the VEGF-Receptor 2 in patients with stage IV and locally advanced pancreatic cancer

The investigational oral DNA vaccine VXM01 targets the vascular endothelial growth factor receptor 2 (VEGFR-2) and uses Salmonella typhi Ty21a as a vector. The immune reaction elicited by VXM01 is expected to disrupt the tumor neovasculature and, consequently, inhibit tumor growth. VXM01 potentially...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Niethammer, Andreas Gerhard (VerfasserIn) , Mikus, Gerd (VerfasserIn) , Knebel, Phillip (VerfasserIn) , Hohmann, Nicolas (VerfasserIn) , Leowardi-Bauer, Christine (VerfasserIn) , Beckhove, Philipp (VerfasserIn) , Akhisaroglu, Mustafa (VerfasserIn) , Ge, Yingzi (VerfasserIn) , Grenacher, Lars (VerfasserIn) , Büchler, Markus W. (VerfasserIn) , Koch, Moritz (VerfasserIn) , Weitz, Jürgen (VerfasserIn) , Haefeli, Walter E. (VerfasserIn) , Schmitz-Winnenthal, Friedrich Hubertus (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: 20 August 2012
In: BMC cancer
Year: 2012, Jahrgang: 12
ISSN:1471-2407
DOI:10.1186/1471-2407-12-361
Online-Zugang:Resolving-System, kostenfrei, Volltext: http://dx.doi.org/10.1186/1471-2407-12-361
Verlag, kostenfrei, Volltext: https://bmccancer.biomedcentral.com/articles/10.1186/1471-2407-12-361
Volltext
Verfasserangaben:Andreas G. Niethammer, Heinz Lubenau, Gerd Mikus, Philipp Knebel, Nicolas Hohmann, Christine Leowardi, Philipp Beckhove, Mustafa Akhisaroglu, Yingzi Ge, Marco Springer, Lars Grenacher, Markus W. Buchler, Moritz Koch, Jürgen Weitz, Walter E. Haefeli and Friedrich H. Schmitz-Winnenthal
Beschreibung
Zusammenfassung:The investigational oral DNA vaccine VXM01 targets the vascular endothelial growth factor receptor 2 (VEGFR-2) and uses Salmonella typhi Ty21a as a vector. The immune reaction elicited by VXM01 is expected to disrupt the tumor neovasculature and, consequently, inhibit tumor growth. VXM01 potentially combines the advantages of anti-angiogenic therapy and active immunotherapy.
Beschreibung:Gesehen am 28.08.2018
Beschreibung:Online Resource
ISSN:1471-2407
DOI:10.1186/1471-2407-12-361

Ähnliche Einträge